Literature DB >> 17118570

Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.

Krzysztof Bujko1, Wojciech Michalski, Lucyna Kepka, Marek P Nowacki, Anna Nasierowska-Guttmejer, Piotr Tokar, Dariusz Dymecki, Mariusz Pawlak, Tadeusz Lesniak, Piotr Richter, Andrzej Wojnar, Ewa Chmielik.   

Abstract

PURPOSE: To compare 5 x 5 Gy preoperative radiotherapy with immediate surgery vs. preoperative chemoradiotherapy (50.4 Gy, 5-fluorouracil, leucovorin) with delayed surgery in a randomized trial for cT3-T4 low-lying rectal cancer. Despite the downstaging effect of chemoradiotherapy, similar long-term outcomes were observed in both groups.
METHODS: The Cox model was used to evaluate the prognostic value of ypTN ("yp" denotes that pathologic classification was performed after initial multimodality therapy) categories and the surgical margin status in 291 patients.
RESULTS: Disease-free survival (DFS) (hazard ratio [HR] 1.05, 95% confidence interval [CI], 0.73-1.51), distant metastases (HR, 1.17; 95% CI, 0.77-1.78), and local control (HR, 1.45; 95% CI, 0.74-2.84) were similar in both arms. The ypN status was the only independent prognostic factor for DFS (p < 0.001). An interaction (p = 0.016) between N stage and the assigned treatment was demonstrated. For ypN-negative patients, DFS was similar in both arms (HR, 0.83, 95% CI, 0.47-1.48); however, for ypN-positive patients, DFS was worse in the chemoradiotherapy arm (HR, 1.73; 95% CI, 1.07-2.77). The 4-year (median follow-up) DFS rate in N-positive patients was 51% in the 5 x 5-Gy arm vs. 25% in the chemoradiotherapy arm. The corresponding 4-year rates for the incidence of local recurrence and distant metastases were 14% vs. 27% (HR, 1.95; 95% CI, 0.78-4.86) and 38% vs. 68% (HR, 2.05; 95% CI, 1.21-3.48).
CONCLUSION: N-positive disease after chemoradiotherapy indicates radiochemoresistance. N-positive disease after 5 x 5 Gy RT includes both radiosensitive and radioresistant tumors, because the interval between radiotherapy and surgery was too short for radiosensitive cancer to undergo necrosis. Thus, the greater risk of distant metastases recorded in the chemoradiotherapy arm suggests that radiochemoresistance of nodal metastases from rectal cancer is associated with a high potential for developing distant metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118570     DOI: 10.1016/j.ijrobp.2006.08.065

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.

Authors:  Yuji Toiyama; Yasuhiro Inoue; Mikio Kawamura; Aya Kawamoto; Yoshinaga Okugawa; Jyunichiro Hiro; Susumu Saigusa; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int Surg       Date:  2015-02

2.  Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.

Authors:  Antonio Avallone; Luigi Aloj; Corradina Caracò; Paolo Delrio; Biagio Pecori; Fabiana Tatangelo; Nigel Scott; Rossana Casaretti; Francesca Di Gennaro; Massimo Montano; Lucrezia Silvestro; Alfredo Budillon; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

Review 3.  Update on advances and controversy in rectal cancer treatment.

Authors:  S Biondo; D Fraccalvieri; T Golda; R Frago; L Trenti; E Kreisler
Journal:  Tech Coloproctol       Date:  2016-01-12       Impact factor: 3.781

4.  Prognostic significance of adverse events associated with preoperative radiotherapy for rectal cancer.

Authors:  Soichiro Ishihara; Toshiaki Watanabe; Takuya Akahane; Ryu Shimada; Atsushi Horiuchi; Hajima Shibuya; Tamuro Hayama; Hideki Yamada; Keijiro Nozawa; Hiroshi Igaki; Keiji Matsuda
Journal:  Int J Colorectal Dis       Date:  2011-02-22       Impact factor: 2.571

5.  Preoperative radiochemotherapy in t3 operable low rectal cancers: a gold standard?

Authors:  Claudio Fucini; Filippo Pucciani; Claudio Elbetti; Riccardo Gattai; Antonio Russo
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 6.  Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

Authors:  C Grávalos; P García-Alfonso; R Afonso; V Arrazubi; A Arrivi; J C Cámara; J Capdevila; A Gómez-España; A Lacasta; J L Manzano; M Salgado; J Sastre; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

7.  Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer.

Authors:  Kyungyeon Hwang; In Ja Park; Chang Sik Yu; Seok-Byung Lim; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Jin Cheon Kim
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

Review 8.  Advances in radiotherapy in operable rectal cancer.

Authors:  Aravind Suppiah; John E Hartley; John R T Monson
Journal:  Dig Surg       Date:  2009-06-03       Impact factor: 2.588

9.  Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy.

Authors:  Aya Kawamoto; Koji Tanaka; Susumu Saigusa; Yuji Toiyama; Yuhki Morimoto; Hiroyuki Fujikawa; Takashi Iwata; Kohei Matsushita; Takeshi Yokoe; Hiromi Yasuda; Yasuhiro Inoue; Chikao Miki; Masato Kusunoki
Journal:  Exp Ther Med       Date:  2011-12-28       Impact factor: 2.447

10.  Prognostic significance of early complete response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy: Multicentric study of Turkish Society for Radiation Oncology Group (TROD).

Authors:  Diclehan Kılıç; Fatma Sert; İlknur Bilkay Görken; Zümre Arıcan Alıcıkuş; Nesrin Aktürk; Esra Kaytan Sağlam; Ahmet Kizir; Serdar Özkök; Hasan Taylan Yılmaz; Füsun Göçen; Deniz Yalman
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.